Startups
We are a medical technology company developing next-generation solutions for the treatment of chronic venous insufficiency, a progressive medical condition affecting an estimated 10% of adults.
Our Mission
To improve the physician and patient experience during chronic venous insufficiency treatment by commercializing the next-generation RF therapy.
Our Mission
To improve the physician and patient experience during chronic venous insufficiency treatment by commercializing the next-generation RF therapy.
Overview
Location
United States, California, San Jose
Employees
11-50
Total raised
$27M
Founded date
2014
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Ally Bridge Group | ally-bridge.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 6, 2019 | Venclose brings in $27 million Series C to market venous reflux solution | According to Gibson, the company will need the extra help to keep up with the market. The device received FDA 510(k) approval around two years ago and appears to be gaining ground. “This month, after less than two years of having this produ... |
| Dec 4, 2019 | Venclose closes $27m Series C | Venous reflux disease treatment developer Venclose announced that it closed a Series C funding round totaling $27 million. Venclose develops the next-generation Venclose RF ablation system designed to close damaged veins and restore healthy... |
| Dec 4, 2019 | Ally Bridge Group Leads Venclose’s $27 Million Series C Funding | SAN JOSE, Calif., Dec. 3, 2019 /PRNewswire/ — Venclose, Inc., a privately-held Silicon Valley medical device company focused on innovative treatment procedures for venous reflux disease, today announced it has closed its Series C funding le... |
| Dec 4, 2019 | Venclose closes $27M Series C funding to develop new solutions for the treatment of venous reflux disease | Venous reflux disease, also known as chronic venous insufficiency (CVI). CVI is a progressive medical condition affecting more than 40 million adults in the United States alone. Venclose is a Silicon Valley medical technology startup develo... |
| Dec 3, 2019 | Venclose Raises $27M in Series C Funding | Venclose, Inc., a San Jose, CA-based medical device company focused on innovative treatment procedures for venous reflux disease, closed a $27m Series C funding. The round was led by Ally Bridge Group (ABG), a global life science-focused gr... |
| Jul 12, 2018 | Medtech Company Venclose Closes Series B Financing Round | Venclose, Inc., a San Jose, CA-based medical technology company developing next-generation solutions for the treatment of venous reflux disease, closed a Series B round of financing. New and existing investors participated in the round. The... |
| Venclose brings in $27 million Series C to market venous reflux solution | The Venclose thermal ablation system Venclose, a San Jose-based medical device company, just received $27 million in a Series C round led by the Ally Bridge Group. The funding will support the company’s efforts to market its radio frequency... |
Reviews 0
FAQ about Venclose
When was Venclose founded?
Venclose was founded in 2014.
How much funding has Venclose raised?
Venclose has raised $27M in total across 1 funding round.
Who has invested in Venclose?
Parsers VC lists 2 investors of Venclose, among them Ally Bridge Group.
What has the press written about Venclose?
Parsers VC has collected 8 articles mentioning Venclose, among them “Venclose brings in $27 million Series C to market venous reflux solution” (Dec 6, 2019) and “Venclose closes $27m Series C” (Dec 4, 2019).
Is Venclose still active?
Yes, Venclose is active; its latest activity on Parsers VC dates from Nov 30, 2020.